{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:43:55Z","timestamp":1789011835863,"version":"build-2803163510"},"reference-count":40,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,12,10]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>There was no significant difference in response rates, PFS, or OS among patients that developed resistance to different lenalidomide doses. Longer duration of prior lenalidomide and a longer lenalidomide-free interval are associated with better outcomes with pomalidomide.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019000539","type":"journal-article","created":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T11:32:24Z","timestamp":1575977544000},"page":"4095-4103","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":22,"title":["Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide\/dexamethasone"],"prefix":"10.1182","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8191-5832","authenticated-orcid":false,"given":"Efstathios","family":"Kastritis","sequence":"first","affiliation":[{"name":"Department of Clinical Therapeutics,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Roussou","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gavriatopoulou","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Kanellias","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalini","family":"Migkou","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3407-5994","authenticated-orcid":false,"given":"Evangelos","family":"Eleutherakis-Papaiakovou","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2620-4004","authenticated-orcid":false,"given":"Dimitrios C.","family":"Ziogas","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Despina","family":"Fotiou","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6328-9783","authenticated-orcid":false,"given":"Ioannis","family":"Ntanasis-Stathopoulos","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Dialoupi","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavroula","family":"Giannouli","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Tsirigotis","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Propaedeutic, ''ATTIKON'' General University Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sossana","family":"Delimpasi","sequence":"additional","affiliation":[{"name":"Department of Haematology, Evangelismos Hospital, Athens, Greece; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Despina","family":"Mparmparousi","sequence":"additional","affiliation":[{"name":"Haematology Laboratory and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mairylin","family":"Spyropoulou-Vlachou","sequence":"additional","affiliation":[{"name":"Immunology Laboratory, Alexandra Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Xirokosta","sequence":"additional","affiliation":[{"name":"Haematology Laboratory and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5133-1422","authenticated-orcid":false,"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2019,12,10]]},"reference":[{"issue":"5","key":"2019121011321766800_B1","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc3257","article-title":"The genetic architecture of multiple myeloma","volume":"12","author":"Morgan","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"2019121011321766800_B2","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1182\/blood-2012-01-405985","article-title":"Clonal competition with alternating dominance in multiple myeloma","volume":"120","author":"Keats","year":"2012","journal-title":"Blood"},{"issue":"8","key":"2019121011321766800_B3","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1038\/leu.2014.13","article-title":"Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma","volume":"28","author":"Melchor","year":"2014","journal-title":"Leukemia"},{"issue":"9","key":"2019121011321766800_B4","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nrc.2017.63","article-title":"Evolutionary biology of high-risk multiple myeloma","volume":"17","author":"Pawlyn","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"2019121011321766800_B5","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1038\/s41375-018-0153-6","article-title":"Multiple myeloma clonal evolution in homogeneously treated patients","volume":"32","author":"Corre","year":"2018","journal-title":"Leukemia"},{"issue":"29","key":"2019121011321766800_B6","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019121011321766800_B7","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl J Med"},{"issue":"17","key":"2019121011321766800_B8","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1182\/blood-2010-04-279893","article-title":"Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma","volume":"116","author":"G\u00f6rg\u00fcn","year":"2010","journal-title":"Blood"},{"issue":"11","key":"2019121011321766800_B9","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"Miguel","year":"2013","journal-title":"Lancet Oncol"},{"issue":"21","key":"2019121011321766800_B10","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.408.408","article-title":"Final analysis, cytogenetics, long-term treatment, and long-term survival in MM-003, a phase 3 study comparing pomalidomide + low-dose dexamethasone (POM + LoDEX) vs high-dose dexamethasone (HiDEX) in relapsed\/refractory multiple myeloma (RRMM) [abstract]","volume":"122","author":"Dimopoulos","year":"2013","journal-title":"Blood"},{"issue":"12","key":"2019121011321766800_B11","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1182\/blood-2013-11-538835","article-title":"Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study","volume":"123","author":"Richardson","year":"2014","journal-title":"Blood"},{"issue":"21","key":"2019121011321766800_B12","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.4755.4755","article-title":"Pomalidomide + low-dose dexamethasone in patients with refractory or relapsed and refractory multiple myeloma and renal impairment: analysis of patients from the phase 3b stratus trial (MM-010) [abstract]","volume":"124","author":"Weisel","year":"2014","journal-title":"Blood"},{"key":"2019121011321766800_B13","first-page":"5393","article-title":"MM-008: a phase 1 trial evaluating pharmacokinetics and tolerability of pomalidomide + low-dose dexamethasone in patients with relapsed or refractory and refractory multiple and renal impairment","volume-title":"Blood","author":"Matous","year":"2013"},{"issue":"4","key":"2019121011321766800_B14","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood-2016-02-700872","article-title":"Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma","volume":"128","author":"Dimopoulos","year":"2016","journal-title":"Blood"},{"issue":"16","key":"2019121011321766800_B15","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1182\/blood-2013-03-488676","article-title":"Pomalidomide, cyclophosphamide, and prednisone for relapsed\/refractory multiple myeloma: a multicenter phase 1\/2 open-label study","volume":"122","author":"Larocca","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2019121011321766800_B16","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/hon.2290","article-title":"Safety and tolerability of pomalidomide-based regimens (pomalidomide-carfilzomib-dexamethasone with or without cyclophosphamide) in relapsed\/refractory multiple myeloma and severe renal dysfunction: a case series","volume":"35","author":"Richter","year":"2017","journal-title":"Hematol Oncol"},{"issue":"21","key":"2019121011321766800_B17","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1182\/blood-2015-11-682518","article-title":"Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma","volume":"127","author":"Baz","year":"2016","journal-title":"Blood"},{"issue":"24","key":"2019121011321766800_B18","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1182\/blood-2018-07-863829","article-title":"Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma","volume":"132","author":"Garderet","year":"2018","journal-title":"Blood"},{"issue":"22","key":"2019121011321766800_B19","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.3316.3316","article-title":"A phase I\/II trial of ixazomib (Ix), pomalidomide (POM), and dexamethasone (DEX), in relapsed\/refractory (R\/R) multiple myeloma (MM) patients: responses in double\/triple refractory myeloma and poor risk cytogenetics [abstract]","volume":"128","author":"Krishnan","year":"2016","journal-title":"Blood"},{"issue":"22","key":"2019121011321766800_B20","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.1145.1145","article-title":"A multicenter, open label phase I\/II study of carfilzomib, pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma (MM) patients [abstract]","volume":"128","author":"Bringhen","year":"2016","journal-title":"Blood"},{"issue":"8","key":"2019121011321766800_B21","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","article-title":"Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"130","author":"Chari","year":"2017","journal-title":"Blood"},{"issue":"19","key":"2019121011321766800_B22","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N Engl J Med"},{"issue":"10","key":"2019121011321766800_B23","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1182\/blood-2017-05-782961","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma","volume":"130","author":"Paludo","year":"2017","journal-title":"Blood"},{"issue":"12","key":"2019121011321766800_B24","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1038\/leu.2017.173","article-title":"Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma [published correction appears in Leukemia. 2018;32(10):2305]","volume":"31","author":"Richardson","year":"2017","journal-title":"Leukemia"},{"issue":"9","key":"2019121011321766800_B25","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma [published corrections appear in Leukemia. 2006;20(9):2220 and Leukemia. 2007;21(5):1134]","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"issue":"18","key":"2019121011321766800_B26","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2019121011321766800_B27","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/leu.2015.356","article-title":"Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group","volume":"30","author":"Laubach","year":"2016","journal-title":"Leukemia"},{"issue":"20","key":"2019121011321766800_B28","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1182\/blood-2014-11-568923","article-title":"Treatment options for relapsed and refractory multiple myeloma","volume":"125","author":"Nooka","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2019121011321766800_B29","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/bjh.12805","article-title":"The impact of intra-clonal heterogeneity on the treatment of multiple myeloma","volume":"165","author":"Brioli","year":"2014","journal-title":"Br J Haematol"},{"issue":"13","key":"2019121011321766800_B30","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1182\/blood-2016-06-723007","article-title":"Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma","volume":"128","author":"Weinhold","year":"2016","journal-title":"Blood"},{"issue":"11","key":"2019121011321766800_B31","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1038\/sj.leu.2404800","article-title":"Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolution","volume":"21","author":"Stewart","year":"2007","journal-title":"Leukemia"},{"issue":"5","key":"2019121011321766800_B32","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1182\/blood-2012-01-405977","article-title":"Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides","volume":"120","author":"Egan","year":"2012","journal-title":"Blood"},{"issue":"21","key":"2019121011321766800_B33","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.1969.1969","article-title":"MM-005: a phase 1 trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and\/or refractory multiple myeloma (RRMM) [abstract]","volume":"122","author":"Richardson","year":"2013","journal-title":"Blood"},{"issue":"21","key":"2019121011321766800_B34","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.304.304","article-title":"Pomalidomide, bortezomib and dexamethasone (PVD) for patients with relapsed lenalidomide refractory multiple myeloma (MM) [abstract]","volume":"124","author":"Lacy","year":"2014","journal-title":"Blood"},{"issue":"21","key":"2019121011321766800_B35","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.690.690","article-title":"Phase I\/II dose expansion of a multi-center trial of carfilzomib and pomalidomide with dexamethasone (Car-Pom-d) in patients with relapsed\/refractory multiple myeloma [abstract]","volume":"122","author":"Shah","year":"2013","journal-title":"Blood"},{"issue":"20","key":"2019121011321766800_B36","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1182\/blood-2015-05-643320","article-title":"Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma","volume":"126","author":"Shah","year":"2015","journal-title":"Blood"},{"issue":"22","key":"2019121011321766800_B37","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.4516.4516","article-title":"Daratumumab single agent and daratumumab plus pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma: a real life retrospective evaluation [abstract]","volume":"128","author":"Branca","year":"2016","journal-title":"Blood"},{"issue":"22","key":"2019121011321766800_B38","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.492.492","article-title":"Clinical efficacy of daratumumab, pomalidomide and dexamethasone in relapsed, refractory myeloma patients: utility of retreatment with daratumumab among refractory patients [abstract]","volume":"128","author":"Nooka","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2019121011321766800_B39","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1182\/blood-2017-10-809293","article-title":"The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents","volume":"131","author":"Gavriatopoulou","year":"2018","journal-title":"Blood"},{"issue":"6","key":"2019121011321766800_B40","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial","volume":"20","author":"Richardson","year":"2019","journal-title":"Lancet Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/23\/4095\/1547217\/advancesadv2019000539.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/23\/4095\/1547217\/advancesadv2019000539.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T11:32:40Z","timestamp":1575977560000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/23\/4095\/429589\/Impact-of-last-lenalidomide-dose-duration-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,10]]},"references-count":40,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2019,12,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019000539","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,10]]}}}